Search
Elsulfavirine
go.drugbank.com/drugs/DB14929InvestigationalElsulfavirine is under investigation in clinical trial NCT03706898 (Study to Evaluate the Safety and PK of Elpida® in Healthy Subjects and Patients With Hepatic Impairment and to Assess the Impact of Food
Menaquinone 6
go.drugbank.com/drugs/DB14936InvestigationalMenaquinone 6 is under investigation in clinical trial NCT01194778 (Comparison of Efficacy of Different Dosages Vitamin K2).
Synonyms: Menaquinone 6Categories: Vitamin K 2, Vitamin KEtirinotecan pegol
go.drugbank.com/drugs/DB14951InvestigationalEtirinotecan pegol is under investigation in clinical trial NCT01663012 (Phase II NKTR-102 In Bevacizumab-Resistant High Grade Glioma).
Categories: Topoisomerase 1 (TOP1) inhibitorsPamrevlumab
go.drugbank.com/drugs/DB14952InvestigationalPamrevlumab is under investigation in clinical trial NCT00913393 (Study of FibroGen (FG)-3019 in Subjects With Type 2 Diabetes Mellitus and Kidney Disease on ACEi and/or ARB Therapy).
Firtecan pegol
go.drugbank.com/drugs/DB14953InvestigationalFirtecan pegol is under investigation in clinical trial NCT01036113 (A Phase 2 Study of EZN-2208 in Patients With Metastatic Breast Cancer).
MK-3577
go.drugbank.com/drugs/DB14957InvestigationalMK-3577 is under investigation in clinical trial NCT00868790 (A Study of the Safety and Efficacy of MK-3577 in Participants With Type 2 Diabetes Mellitus (MK-3577-009)).
CTT-1057
go.drugbank.com/drugs/DB14965InvestigationalCTT-1057 is under investigation in clinical trial NCT03427476 (CTT1057, a Small Molecular Inhibitor of PSMA, as a Novel Imaging Agent of Neovascularization in Renal Cell Carcinoma).
MIP-1095 I-131
go.drugbank.com/drugs/DB14978InvestigationalMIP-1095 I-131 is under investigation in clinical trial NCT03030885 (Use of an Experimental Radiopharmaceutical (131I-MIP-1095) in Men With Metastatic Castration-Resistant Prostate Cancer (mCRPC)).
Nomacopan
go.drugbank.com/drugs/DB14991InvestigationalNomacopan is under investigation in clinical trial NCT03427060 (Coversin in PNH in Patients With Resistance to Eculizumab Due to Complement C5 Polymorphisms).
Categories: Recombinant Protein Inhibitor of Complement Factor 5Pegunigalsidase alfa
go.drugbank.com/drugs/DB14992ApprovedInvestigationalPegunigalsidase alfa (PRX-102) is a recombinant form of human α-galactosidase-A indicated for long-term enzyme replacement therapy in patients with Fabry disease, a rare genetic disorder characterized … to a different glycosylation pattern.